SCHEMBL20178562

SCHEMBL20178562

CCc1ccc(C(=O)O)c(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
CES2 O00748 2/20 0.44
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
METAP2 P50579 2/20 0.43
HPGD P15428 3/20 0.42
KDM4E B2RXH2 2/20 0.42
HSD17B10 Q99714 2/20 0.42
RXRA P19793 3/20 0.41
RXRB P28702 3/20 0.41
RXRG P48443 2/20 0.41
ASPH Q12797 1/20 0.41
USP2 O75604 2/20 0.41
MEN1 O00255 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP2C19 P33261 1/20 0.41
PPARA Q07869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23370109 0.88 CES2 (0.43) ALDH1A1CES2PTGS1PTGS2RXRA
SCHEMBL23370103 0.86 GPR52 (0.45) ALDH1A1CES2SMN1; SMN2KDM4EESRRG
SCHEMBL14010461 0.86 CES2 (0.42) ALDH1A1CES2PTGS1PTGS2KDM4E
SCHEMBL10309762 0.85 CFTR (0.49) ALDH1A1CES2HPGDKDM4EHSD17B10
SCHEMBL3670006 0.84 CES2 (0.46) ALDH1A1CES2HPGDKDM4EHSD17B10
SCHEMBL20178587 0.83 PPARA (0.57) ALDH1A1METAP2HPGDKDM4EHSD17B10
SCHEMBL25489233 0.83 CES2 (0.42) ALDH1A1CES2PTGS2HPGDKDM4E
SCHEMBL4465339 0.82 MLYCD (0.43) CES2HPGDTSHRESRRG
SCHEMBL3661976 0.82 CES2 (0.44) ALDH1A1CES2HPGDKDM4EHSD17B10
SCHEMBL29338525 0.82 ALDH1A1 (0.46) ALDH1A1CES2HPGDKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020263703-A1 ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS STRATOS GENOMICS, INC. (US) 2020-12-30 WO disclosed
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 ALDH1A1 2185/4885CES2 1536/4885PTGS1 826/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 ALDH1A1 2185/4885CES2 1536/4885PTGS1 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.